~ Buy the KISQALI (ribociclib succinate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR KISQALI

All Clinical Trials for Kisqali

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02035813 ↗	DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).	Recruiting	Prof. W. Janni	Phase 2	2014-01-01	Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer (MBC). However, even if the prognostic value of CTCs in MBC is well understood, the role of both CTC prevalence and CTC phenotype in predicting treatment response needs further investigation. DETECT IV is a prospective, multicenter, open-label, phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). Additional research on CTC dynamics and characteristics will provide a better understanding of the prognostic and predictive value of CTCs and is one step into a more personalized therapy for MBC.
NCT02344472 ↗	Detect V / CHEVENDO (Chemo vs. Endo)	Recruiting	Celgene Corporation	Phase 3	2015-09-01	Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
NCT02344472 ↗	Detect V / CHEVENDO (Chemo vs. Endo)	Recruiting	DETECT study group	Phase 3	2015-09-01	Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
NCT02344472 ↗	Detect V / CHEVENDO (Chemo vs. Endo)	Recruiting	Eisai GmbH	Phase 3	2015-09-01	Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
NCT02344472 ↗	Detect V / CHEVENDO (Chemo vs. Endo)	Recruiting	Novartis Pharmaceuticals	Phase 3	2015-09-01	Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.

Clinical Trial Conditions for Kisqali

Condition Name

Condition Name for Kisqali
Intervention	Trials
Breast Cancer	8
HER2-Negative Breast Cancer	4
Metastatic Breast Cancer	4
Anatomic Stage IV Breast Cancer AJCC v8	3

Condition MeSH

Condition MeSH for Kisqali
Intervention	Trials
Breast Neoplasms	21
Neoplasms	7
Glioma	3
Carcinoma	3

Clinical Trial Locations for Kisqali

Trials by Country

Trials by Country for Kisqali
Location	Trials
United States	46
Germany	6
Spain	3
Australia	3
Netherlands	3

Trials by US State

Trials by US State for Kisqali
Location	Trials
Texas	6
District of Columbia	4
Massachusetts	4
California	4
Ohio	3

Clinical Trial Progress for Kisqali

Clinical Trial Phase

Clinical Trial Phase for Kisqali
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	2
Phase 2	15

Clinical Trial Status

Clinical Trial Status for Kisqali
Clinical Trial Phase	Trials
Not yet recruiting	12
Recruiting	11
Active, not recruiting	6

Clinical Trial Sponsors for Kisqali

Sponsor Name

Sponsor Name for Kisqali
Sponsor	Trials
Novartis	14
National Cancer Institute (NCI)	7
Novartis Pharmaceuticals	5

Sponsor Type

Sponsor Type for Kisqali
Sponsor	Trials
Industry	39
Other	36
NIH	7